European Commission approves Cabometyx + Opdivo for first-line advanced renal cell carcinoma

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The European Commission has approved Cabometyx (cabozantinib) in combination Opdivo (nivolumab) for the first-line treatment of advanced renal cell carcinoma.

To access this subscriber-only content please log in or renew you subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Login